← Eichor
Study identifier: NCT06358222 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Predicting Non-small Cell Lung Cancer (NSCLC) Lymph Node Metastasis: Integrating Circulating Tumor DNA (ctDNA) Mutation/ Methylation Profiling With Positron Emission Tomography-computed Tomography (PET-CT) Scan

Condition: Carcinoma · Non-small Cell Lung Cancer  ·  Sponsor: Shanghai Chest Hospital

PhaseN/A
Planned participants200
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

This is a single center, prospective and observational study conducted in three stages to predict the NSCLC lymph node metastasis based on ctDNA/specific methylation molecular features combined with PET-CT imaging features and intervention study.

This description comes directly from the study's public registry record.

Talk to the study team

Feng Yao, PhD  ·  021-2220000  ·  yaofeng@shsmu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Shanghai Chest HospitalShanghai, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06358222